Cantor Fitzgerald Weighs in on Kura Oncology FY2025 Earnings

Kura Oncology, Inc. (NASDAQ:KURAFree Report) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Kura Oncology in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek forecasts that the company will earn ($2.94) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share.

Kura Oncology (NASDAQ:KURAGet Free Report) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.64) by $0.01. During the same period in the previous year, the company posted ($0.50) EPS.

Other equities research analysts also recently issued reports about the stock. Wedbush reiterated an “outperform” rating and set a $37.00 price target on shares of Kura Oncology in a report on Monday, November 4th. StockNews.com cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a research note on Wednesday, November 20th. Stifel Nicolaus lowered Kura Oncology from a “buy” rating to a “hold” rating and reduced their price target for the stock from $26.00 to $19.00 in a research note on Monday, October 14th. HC Wainwright lifted their price objective on Kura Oncology from $32.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, November 21st. Finally, Bank of America reduced their target price on Kura Oncology from $36.00 to $29.00 and set a “buy” rating on the stock in a research report on Friday, November 22nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $27.38.

Check Out Our Latest Analysis on KURA

Kura Oncology Trading Up 1.8 %

Kura Oncology stock opened at $7.39 on Wednesday. The stock has a 50-day moving average price of $10.08 and a 200 day moving average price of $16.15. Kura Oncology has a 52 week low of $6.98 and a 52 week high of $24.17. The stock has a market cap of $574.68 million, a PE ratio of -3.13 and a beta of 0.81. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02.

Institutional Trading of Kura Oncology

A number of institutional investors have recently modified their holdings of the company. nVerses Capital LLC purchased a new position in Kura Oncology in the third quarter valued at approximately $25,000. The Manufacturers Life Insurance Company lifted its holdings in shares of Kura Oncology by 5.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock valued at $793,000 after acquiring an additional 1,976 shares in the last quarter. Harbor Capital Advisors Inc. boosted its position in Kura Oncology by 4.4% during the 4th quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock worth $430,000 after purchasing an additional 2,076 shares during the period. Hsbc Holdings PLC increased its holdings in Kura Oncology by 13.4% in the 2nd quarter. Hsbc Holdings PLC now owns 18,300 shares of the company’s stock valued at $374,000 after purchasing an additional 2,167 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in Kura Oncology by 0.8% in the third quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company’s stock valued at $7,997,000 after purchasing an additional 3,092 shares during the period.

Kura Oncology Company Profile

(Get Free Report)

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

See Also

Earnings History and Estimates for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.